Lifetime Costs for Treated Follicular Lymphoma Patients in the US-Reference-Cited by-同舟云学术

Lifetime Costs for Treated Follicular Lymphoma Patients in the US

Published:2021-07-17 Issue:10 Volume:39 Page:1163-1183
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Eichten Caitlin,Ma Qiufei,Delea Thomas E.^ORCID,Hagiwara May,Ramos Roberto,Iorga Şerban R.,Zhang Jie,Maziarz Richard T.

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01052-3.pdf

Reference55 articles.

1. Surveillance Epidemiology and End Results Program. Cancer stat facts: NHL—follicular lymphoma: National Cancer Institute; 2020. [cited 2020 June 26]. Available from: https://seer.cancer.gov/statfacts/html/follicular.html.

2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28. https://doi.org/10.1093/jnci/djq495 (Epub 2011/01/14).

3. Bachy E, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, et al. sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31):2815–24. https://doi.org/10.1200/JCO.19.01073 (Epub 2019/07/25).

4. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853–8. https://doi.org/10.1200/JCO.2009.26.5827 (Epub 2010/05/05).

5. Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol. 2019;37(11):912–22. https://doi.org/10.1200/JCO.18.00915 (Epub 2019/02/12).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis;Cancers;2023-09-02

2. Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma;Investigational New Drugs;2023-08-12

3. Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis;Annals of Translational Medicine;2022-03

4. Lifetime costs of follicular lymphoma high in the USA;PharmacoEconomics & Outcomes News;2021-08